A complete 4DCT-ventilation functional avoidance virtual trial: Developing strategies for prospective clinical trials

Timothy Waxweiler, Leah Schubert, Quentin Diot, Austin Faught, Kelly Stuhr, Richard Castillo, Edward Castillo, Thomas Guerrero, Chad Rusthoven, Laurie Gaspar, Brian Kavanagh, Moyed Miften, Yevgeniy Vinogradskiy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Introduction: 4DCT-ventilation is an exciting new imaging modality that uses 4DCT data to calculate lung-function maps. Because 4DCTs are acquired as standard of care for lung cancer patients undergoing radiotherapy, 4DCT-ventiltation provides functional information at no extra dosimetric or monetary cost to the patient. The development of clinical trials is underway to use 4DCT-ventilation imaging to spare functional lung in patients undergoing radiotherapy. The purpose of this work was to perform a virtual trial using retrospective data to develop the practical aspects of a 4DCT-ventilation functional avoidance clinical trial. Methods: The study included 96 stage III lung cancer patients. A 4DCT-ventilation map was calculated using the patient's 4DCT-imaging, deformable registration, and a density-change-based algorithm. Clinical trial inclusion assessment used quantitative and qualitative metrics based on the patient's spatial ventilation profile. Clinical and functional plans were generated for 25 patients. The functional plan aimed to reduce dose to functional lung while meeting standard target and critical structure constraints. Standard and dose-function metrics were compared between the clinical and functional plans. Results: Our data showed that 69% and 59% of stage III patients have regional variability in function based on qualitative and quantitative metrics, respectively. Functional planning demonstrated an average reduction of 2.8 Gy (maximum 8.2 Gy) in the mean dose to functional lung. Conclusions: Our work demonstrated that 60-70% of stage III patients would be eligible for functional planning and that a typical functional lung mean dose reduction of 2.8 Gy can be expected relative to standard clinical plans. These findings provide salient data for the development of functional clinical trials.

Original languageEnglish (US)
Pages (from-to)144-152
Number of pages9
JournalJournal of Applied Clinical Medical Physics
Volume18
Issue number3
DOIs
StatePublished - May 1 2017

Fingerprint

avoidance
ventilation
Ventilation
lungs
Clinical Trials
Radiotherapy
Imaging techniques
Lung
dosage
Planning
planning
radiation therapy
Lung Neoplasms
cancer
Standard of Care
Costs
inclusions
costs
Costs and Cost Analysis

Keywords

  • CT ventilation
  • Functional imaging
  • Lung cancer

ASJC Scopus subject areas

  • Radiation
  • Instrumentation
  • Radiology Nuclear Medicine and imaging

Cite this

A complete 4DCT-ventilation functional avoidance virtual trial : Developing strategies for prospective clinical trials. / Waxweiler, Timothy; Schubert, Leah; Diot, Quentin; Faught, Austin; Stuhr, Kelly; Castillo, Richard; Castillo, Edward; Guerrero, Thomas; Rusthoven, Chad; Gaspar, Laurie; Kavanagh, Brian; Miften, Moyed; Vinogradskiy, Yevgeniy.

In: Journal of Applied Clinical Medical Physics, Vol. 18, No. 3, 01.05.2017, p. 144-152.

Research output: Contribution to journalArticle

Waxweiler, T, Schubert, L, Diot, Q, Faught, A, Stuhr, K, Castillo, R, Castillo, E, Guerrero, T, Rusthoven, C, Gaspar, L, Kavanagh, B, Miften, M & Vinogradskiy, Y 2017, 'A complete 4DCT-ventilation functional avoidance virtual trial: Developing strategies for prospective clinical trials', Journal of Applied Clinical Medical Physics, vol. 18, no. 3, pp. 144-152. https://doi.org/10.1002/acm2.12086
Waxweiler, Timothy ; Schubert, Leah ; Diot, Quentin ; Faught, Austin ; Stuhr, Kelly ; Castillo, Richard ; Castillo, Edward ; Guerrero, Thomas ; Rusthoven, Chad ; Gaspar, Laurie ; Kavanagh, Brian ; Miften, Moyed ; Vinogradskiy, Yevgeniy. / A complete 4DCT-ventilation functional avoidance virtual trial : Developing strategies for prospective clinical trials. In: Journal of Applied Clinical Medical Physics. 2017 ; Vol. 18, No. 3. pp. 144-152.
@article{bc77dc94a36848479c21df1112f3dd18,
title = "A complete 4DCT-ventilation functional avoidance virtual trial: Developing strategies for prospective clinical trials",
abstract = "Introduction: 4DCT-ventilation is an exciting new imaging modality that uses 4DCT data to calculate lung-function maps. Because 4DCTs are acquired as standard of care for lung cancer patients undergoing radiotherapy, 4DCT-ventiltation provides functional information at no extra dosimetric or monetary cost to the patient. The development of clinical trials is underway to use 4DCT-ventilation imaging to spare functional lung in patients undergoing radiotherapy. The purpose of this work was to perform a virtual trial using retrospective data to develop the practical aspects of a 4DCT-ventilation functional avoidance clinical trial. Methods: The study included 96 stage III lung cancer patients. A 4DCT-ventilation map was calculated using the patient's 4DCT-imaging, deformable registration, and a density-change-based algorithm. Clinical trial inclusion assessment used quantitative and qualitative metrics based on the patient's spatial ventilation profile. Clinical and functional plans were generated for 25 patients. The functional plan aimed to reduce dose to functional lung while meeting standard target and critical structure constraints. Standard and dose-function metrics were compared between the clinical and functional plans. Results: Our data showed that 69{\%} and 59{\%} of stage III patients have regional variability in function based on qualitative and quantitative metrics, respectively. Functional planning demonstrated an average reduction of 2.8 Gy (maximum 8.2 Gy) in the mean dose to functional lung. Conclusions: Our work demonstrated that 60-70{\%} of stage III patients would be eligible for functional planning and that a typical functional lung mean dose reduction of 2.8 Gy can be expected relative to standard clinical plans. These findings provide salient data for the development of functional clinical trials.",
keywords = "CT ventilation, Functional imaging, Lung cancer",
author = "Timothy Waxweiler and Leah Schubert and Quentin Diot and Austin Faught and Kelly Stuhr and Richard Castillo and Edward Castillo and Thomas Guerrero and Chad Rusthoven and Laurie Gaspar and Brian Kavanagh and Moyed Miften and Yevgeniy Vinogradskiy",
year = "2017",
month = "5",
day = "1",
doi = "10.1002/acm2.12086",
language = "English (US)",
volume = "18",
pages = "144--152",
journal = "Journal of applied clinical medical physics / American College of Medical Physics",
issn = "1526-9914",
publisher = "American Institute of Physics Publising LLC",
number = "3",

}

TY - JOUR

T1 - A complete 4DCT-ventilation functional avoidance virtual trial

T2 - Developing strategies for prospective clinical trials

AU - Waxweiler, Timothy

AU - Schubert, Leah

AU - Diot, Quentin

AU - Faught, Austin

AU - Stuhr, Kelly

AU - Castillo, Richard

AU - Castillo, Edward

AU - Guerrero, Thomas

AU - Rusthoven, Chad

AU - Gaspar, Laurie

AU - Kavanagh, Brian

AU - Miften, Moyed

AU - Vinogradskiy, Yevgeniy

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Introduction: 4DCT-ventilation is an exciting new imaging modality that uses 4DCT data to calculate lung-function maps. Because 4DCTs are acquired as standard of care for lung cancer patients undergoing radiotherapy, 4DCT-ventiltation provides functional information at no extra dosimetric or monetary cost to the patient. The development of clinical trials is underway to use 4DCT-ventilation imaging to spare functional lung in patients undergoing radiotherapy. The purpose of this work was to perform a virtual trial using retrospective data to develop the practical aspects of a 4DCT-ventilation functional avoidance clinical trial. Methods: The study included 96 stage III lung cancer patients. A 4DCT-ventilation map was calculated using the patient's 4DCT-imaging, deformable registration, and a density-change-based algorithm. Clinical trial inclusion assessment used quantitative and qualitative metrics based on the patient's spatial ventilation profile. Clinical and functional plans were generated for 25 patients. The functional plan aimed to reduce dose to functional lung while meeting standard target and critical structure constraints. Standard and dose-function metrics were compared between the clinical and functional plans. Results: Our data showed that 69% and 59% of stage III patients have regional variability in function based on qualitative and quantitative metrics, respectively. Functional planning demonstrated an average reduction of 2.8 Gy (maximum 8.2 Gy) in the mean dose to functional lung. Conclusions: Our work demonstrated that 60-70% of stage III patients would be eligible for functional planning and that a typical functional lung mean dose reduction of 2.8 Gy can be expected relative to standard clinical plans. These findings provide salient data for the development of functional clinical trials.

AB - Introduction: 4DCT-ventilation is an exciting new imaging modality that uses 4DCT data to calculate lung-function maps. Because 4DCTs are acquired as standard of care for lung cancer patients undergoing radiotherapy, 4DCT-ventiltation provides functional information at no extra dosimetric or monetary cost to the patient. The development of clinical trials is underway to use 4DCT-ventilation imaging to spare functional lung in patients undergoing radiotherapy. The purpose of this work was to perform a virtual trial using retrospective data to develop the practical aspects of a 4DCT-ventilation functional avoidance clinical trial. Methods: The study included 96 stage III lung cancer patients. A 4DCT-ventilation map was calculated using the patient's 4DCT-imaging, deformable registration, and a density-change-based algorithm. Clinical trial inclusion assessment used quantitative and qualitative metrics based on the patient's spatial ventilation profile. Clinical and functional plans were generated for 25 patients. The functional plan aimed to reduce dose to functional lung while meeting standard target and critical structure constraints. Standard and dose-function metrics were compared between the clinical and functional plans. Results: Our data showed that 69% and 59% of stage III patients have regional variability in function based on qualitative and quantitative metrics, respectively. Functional planning demonstrated an average reduction of 2.8 Gy (maximum 8.2 Gy) in the mean dose to functional lung. Conclusions: Our work demonstrated that 60-70% of stage III patients would be eligible for functional planning and that a typical functional lung mean dose reduction of 2.8 Gy can be expected relative to standard clinical plans. These findings provide salient data for the development of functional clinical trials.

KW - CT ventilation

KW - Functional imaging

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85018837581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018837581&partnerID=8YFLogxK

U2 - 10.1002/acm2.12086

DO - 10.1002/acm2.12086

M3 - Article

AN - SCOPUS:85018837581

VL - 18

SP - 144

EP - 152

JO - Journal of applied clinical medical physics / American College of Medical Physics

JF - Journal of applied clinical medical physics / American College of Medical Physics

SN - 1526-9914

IS - 3

ER -